REPERFUSION TREATMENT MARKET ANALYSIS

The global reperfusion treatment market is estimated to be valued at US$ 1,546.7 Million in 2023 and is expected to exhibit a CAGR of 4.7% during the forecast period (2023-2030).

Analysts’ views on Global Reperfusion Treatment Market:

Increasing research and development, new product launches, and strategies like mergers, acquisitions, and collaboration are expected to drive the global reperfusion treatment marketgrowth over the forecast period. For instance, according to the data published by the American College of Radiology on February 2, 2020, myocardial perfusion single-photon emission computed tomography (SPECT) is a well-established, highly standardized test to detect significant coronary artery disease and to stratify patients with regard to cardiac event-free survival. There have been significant advancements in scintillation camera hardware and software that allow decreased image acquisition times and significantly lower injected radiopharmaceutical activity, resulting in lower patient radiation doses. These patient-centered protocols have been designed to preserve or improve image quality andalso decrease the patient’s radiation dose.

Figure 1. Global Reperfusion Treatment Market Share (%), By Injury Type, 2023

To learn more about this report, request a free sample copy

Global Reperfusion Treatment Market– Drivers

Increasing research and development activities related to perfusion treatment

Increasing research and development in the field of perfusion treatment is expected to drive the global reperfusion treatment market growth over the forecast period. For instance, on June 27, 2023, Society of Nuclear Medicine and Molecular Imaging, a journal published an article explaining how a novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity as compared to 99mTc-SPECT myocardial perfusion imaging (MPI). 18F-flurpiridaz PET MPI performed as well in patients with and without obesity while producing images at a lower radiation dosage than 99mTc-SPECT MPI. Obese people frequently suffer from illnesses like diabetes, high cholesterol, and high blood pressure thatincrease their risk of developing CAD. Imaging obese patients for CAD is crucial due to these risk factors.

Figure 2. Global Reperfusion Treatment Market Share (US$ Million), By Region, 2023

To learn more about this report, request a free sample copy

Global Reperfusion Treatment Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global reperfusion treatment market over the forecast period, owing to increasing collaboration by key players. For instance, on July 19, 2023, Inspira Technologies, a company that provides acute respiratory care, announced that it had entered into a collaboration agreement with Perfusion Solution, Inc., perfusion service provider in the U.S. The collaboration combines the INSPIRATM ART100 product with Perfusion Solution's extensive commercial reach and infrastructure in the U.S.

Global Reperfusion Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems regarding the transportation of drugs from one place to another.

However, the COVID-19 pandemic had positive impact on the global reperfusion treatment market, due to increased demand for products for reperfusion treatment. For instance, on March 18, 2020, XVIVO Perfusion, a medical technology company, witnessed increased demand for transplant products due to the COVID-19 epidemic. The planned start of the clinical trials in Europe has been delayed. An action program is being implemented to reduce expenditure. The ongoing COVID-19 epidemic has already led to adjustments and restrictions for most businesses, which is also the case for transplants.

Global Reperfusion Treatment Market- Segmentation

The global reperfusion treatment market report is segmented into treatment type, injury type, distribution channel and region.

Based on treatment type, the global reperfusion treatment market is segmented into therapeutic hypothermia, cyclosporin, stem cell therapy, hydrogen sulphide treatment, and others. Out of which, the stem cell therapy segment is expected to dominate the market due to increasing research and development for advance stem cell therapy.

Based on injury type, the global reperfusion treatment market is segmented into heart injury, kidney injury, intestine injury, and others. Among these, the heart injury segment is expected to dominate the market over the forecast period due to the increasing demand for perfusion treatment in various injury type.

Based on distribution channel, the global reperfusion treatment market is segmented into hospital pharmacies, retail pharmacies, and others. Among these, hospital pharmacies are expected to dominate the market over the forecast period due to advanced facilities for providing treatments in hospital.

Based on Region, the global reperfusion treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Among these, North America is expected to dominate the market due to increasing research and development activities in the region.

Among all segmentation, the treatment type segment has the highest potential due to the increasing research and development for therapeutic Hypothermia. For instance, on July 14, 2021, an article published by Open Urology and Nephrology Journal explained that the administration of Bacillus Calmette-Guérin (BCG) perfusion therapy for CIS of the upper urinary tract (UUT). Radial nephroureterectomy with bladder cuff excision is the recommended course of treatment for UUT urothelium carcinoma (UC). But in patients with risk factors like bilateral tumors, cardiovascular morbidity, and chronic renal failure, nephron-sparing methods are preferred. Antegrade perfusion via nephrostomy and retrograde perfusion by using a ureteric catheter or double-J ureteric stent are the two available administration methods.

Global Reperfusion Treatment Market- Cross Sectional Analysis:

Key market participants in the Europe region are projected to introduce novel therapies and technologies in perfusion therapy, which will fuel the growth of the treatment sector in the area. For instance, on May 14, 2020, Dove Press Ltd, a global publisher, published an article explaining that acardiac malformation, also known as twin reversed arterial perfusion (TRAP) sequence, is a rare complication of monochorionic multiple pregnancy in which "acardic" (lacks a complete cardiac structure), while the other twin, the "pump twin," supplies both circulations.

Global Reperfusion Treatment Market: Key Developments

On January 25, 2021, PEDRA Technology, a company developing perfusion technologies, announced that the U.S. FDA had provide the company a Breakthrough Device Designation for the periprocedural use of its PEDRA Xauron Perfusion System in the treatment of critical limb-threatening ischemia (CLTI). As a result of persistently inadequate blood flow to the lower limbs, CLTI, a severe form of peripheral artery disease (PAD), reported ischemic rest discomfort, tissue loss, or gangrene (tissue death). Untreated CLTI can result in amputation of a limb or death. The death rate is higher than that of most malignancies at five years after the diagnosis of CLTI.

On September 15, 2020, Transcenta, a global biotherapeutics company, announced it had successful scaled up the continuous perfusion process and completed good manufacturing practice (GMP) manufacturing of a novel bispecific antibody for cancer immunotherapy.

Global Reperfusion Treatment Market: Key Trends

Increasing research and development activities

Increasing research and development related to perfusion treatment can drive growth of the market. On January 18, 2023, Journal of Hepatology published an article explaining that machine perfusion is a novel method which is intended to optimize livers before transplantation. However, its effect on morbidity within a 1-year period after transplantation has remained unclear. In this multicenter controlled  clinical trial, researchers randomly assigned livers donated after brain death (DBD) for liver transplantation (LT). Livers were either conventionally cold stored (control group) or cold stored and subsequently treated by 1-2 hypothermic oxygenated perfusions (HOPE) before implantation (HOPE group).

Global Reperfusion Treatment Market: Restraints

Side effects and risks associated with perfusion treatment

The side effects and risks associated with perfusion treatment can hamper the global reperfusion treatment market growth. For instance, on January 3, 2020, according to the Peter MacCallum Cancer Centre, a facility for cancer research, education, and treatment Isolated Limb Perfusion (ILP) is a surgical technique, thus it has risks and side effects. The majority of these risks and side effects are minimal and easily tolerated. Patients will experience some pain, swelling, and redness in the limb following ILP. This lasts six to eight weeks, or two months. In most cases, simple painkillers like paracetamol are used for treatments. After ILP, patients might experience more severe symptoms that necessitate a longer hospital stay. Typically, patients go away on their own without any special care. Although possible, extremely severe side effects are very uncommon.

To counterbalance this restraint, more research and development should be done to avoid side effects and risks for the betterment of patients.

Global Reperfusion Treatment Market- Key Players

Major players operating in the global reperfusion treatment market include Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V, Balmes Transplantation SAS, Revive Therapeutics Ltd, Faraday Pharmaceuticals, Radikal Therapeutics Inc, Amyndas Pharmaceuticals, com, Inc, Angion Biomedica Corp, Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc and Bolder Bio Technology Inc.

*Definition: Reperfusion therapy is used to restore blood flow in blocked arteries after a heart attack. Reperfusion injury usually occurs as a result of organ transplantation and other injuries. Patients are treated with antiplatelet therapy, open or endovascular revascularization, coronary angioplasty, and others. Reperfusion injury can occur in organs such as the heart, kidneys, liver, intestines, lungs, and brain. Clinical trials are currently being conducted with drugs designed to treat reflux injuries.